Kato S, Funakoshi H, Nakamura T, Kato M, Nakano I, et al
Phoenix Pharmaceuticals, also known as Phoenix Peptide, is one of the most historically significant peptide suppliers in North America, founded in 1969 by the scientist who synthesized thyrotropin-releasing hormone (TRH), foundational work that contributed to the discovery of the first neuropeptides
BPC-157 has been thoroughly researched for its therapeutic potential in a variety of conditions, including musculoskeletal injuries, digestive disorders, neurological conditions, autoimmune diseases, and skin and soft tissue injuries
Lowering homocysteine levels reduces endothelial inflammation and oxidative stress, which may help mitigate the micro-vascular clotting issues frequently observed in Long COVID